Novavax, Inc.
$8.67
▼
-3.99%
2026-04-21 08:31:00
www.novavax.com
NMS: NVAX
Explore Novavax, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.41 B
Current Price
$8.67
52W High / Low
$11.97 / $5.8
Stock P/E
3.2
Book Value
$-0.79
Dividend Yield
—
ROCE
76.84%
ROE
-117.16%
Face Value
—
EPS
$2.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
749
Beta
2.65
Debt / Equity
-1.95
Current Ratio
2.13
Quick Ratio
2.1
Forward P/E
-8.01
Price / Sales
1.18
Enterprise Value
$866 M
EV / EBITDA
1.47
EV / Revenue
0.77
Rating
Buy
Target Price
$14
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 2. | AnaptysBio, Inc. | $50.95 | — | $1.46 B | — | 14.7% | -24.49% | $73.3 / $17.11 | $1.33 |
| 3. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
| 4. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 5. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
| 6. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 7. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 147.14 M | 70.44 M | 239.24 M | 626.33 M | 88.31 M |
| Operating Profit | 15.04 M | -80.98 M | 101.07 M | 515.51 M | -131.08 M |
| Net Profit | 17.53 M | -202.38 M | 106.51 M | 518.65 M | -81.03 M |
| EPS in Rs | 0.11 | -1.24 | 0.65 | 3.18 | -0.5 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.12 B | 682.16 M | 556.38 M | 1.6 B |
| Operating Profit | 550.64 M | -248.93 M | -566.51 M | -644.74 M |
| Net Profit | 440.3 M | -187.5 M | -545.06 M | -657.94 M |
| EPS in Rs | 2.7 | -1.15 | -3.35 | -4.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.18 B | 1.56 B | 1.8 B | 2.26 B |
| Total Liabilities | 1.3 B | 2.18 B | 2.51 B | 2.89 B |
| Equity | -127.75 M | -623.84 M | -716.93 M | -634.08 M |
| Current Assets | 978.28 M | 1.13 B | 1.14 B | 1.7 B |
| Current Liabilities | 459.95 M | 1.15 B | 1.64 B | 2.46 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -244.63 M | -87.26 M | -713.97 M | -415.94 M |
| Investing CF | -78.27 M | -204.04 M | -58.81 M | -92.98 M |
| Financing CF | 27.74 M | 260.58 M | 4.47 M | 324.99 M |
| Free CF | -251.02 M | -101.9 M | -772.77 M | -508.92 M |
| Capex | -6.39 M | -14.64 M | -58.81 M | -92.98 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 22.61% | -65.2% | — | — |
| Earnings Growth % | 65.6% | 17.16% | — | — |
| Profit Margin % | -27.49% | -97.97% | -41.15% | — |
| Operating Margin % | -36.49% | -101.82% | -40.32% | — |
| Gross Margin % | 70.28% | 38.21% | 43.55% | — |
| EBITDA Margin % | -15.84% | -87.6% | -37.82% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.